Nontransplant treatment approaches for myeloid neoplasm with mutated TP53

2.

Daver

NG

,

Maiti

A

,

Kadia

TM

, et al.

TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions

.

Cancer Discov

.

2022

;

12

(

11

):

2516

-

2529

.

3.

Molica

M

,

Mazzone

C

,

Niscola

P

,

de Fabritiis

P.

TP53 mutations in acute myeloid leukemia: still a daunting challenge?

Front Oncol

.

2020

;

10

:

610820

.

4.

Takahashi

K

,

Wang

F

,

Kantarjian

H

, et al.

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

.

Lancet Oncol

.

2017

;

18

(

1

):

100

-

111

.

5.

Bernard

E

,

Nannya

Y

,

Hasserjian

RP

, et al.

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

.

Nat Med

.

2020

;

26

(

10

):

1549

-

1556

.

6.

Khoury

JD

,

Solary

E

,

Abla

O

, et al.

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms

.

Leukemia

.

2022

;

36

(

7

):

1703

-

1719

.

7.

Grob

T

,

Al Hinai

ASA

,

Sanders

MA

, et al.

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

.

Blood

.

2022

;

139

(

15

):

2347

-

2354

.

8.

Weinberg

OK

,

Siddon

A

,

Madanat

YF

, et al.

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML

.

Blood Adv

.

2022

;

6

(

9

):

2847

-

2853

.

9.

Arber

DA

,

Orazi

A

,

Hasserjian

RP

, et al.

International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data

.

Blood

.

2022

;

140

(

11

):

1200

-

1228

.

10.

Lindsley

RC

,

Gibson

CJ

,

Murdock

HM

, et al.

Genetic characteristics and outcomes by mutation status in a phase 3 study of CPX-351 versus 7 + 3 in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (AML)

.

Blood

.

2019

;

134

(

suppl 1

):

15

.

11.

Lancet

JE

,

Uy

GL

,

Newell

LF

, et al.

CPX-351 versus 7 + 3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

.

Lancet Haematol

.

2021

;

8

(

7

):

e481

-

e491

.

12.

Othman

J

,

Wilhelm-Benartzi

C

,

Dillon

R

, et al.

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial

.

Blood Adv

.

2023

;

7

(

16

):

4539

-

4549

.

13.

Bally

C

,

Adès

L

,

Renneville

A

, et al.

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

.

Leuk Res

.

2014

;

38

(

7

):

751

-

755

.

14.

Welch

JS

,

Petti

AA

,

Miller

CA

, et al.

TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes

.

N Engl J Med

.

2016

;

375

(

21

):

2023

-

2036

.

15.

Short

NJ

,

Kantarjian

HM

,

Loghavi

S

, et al.

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

.

Lancet Haematol

.

2019

;

6

(

1

):

e29

-

e37

.

16.

Savona

MR

,

McCloskey

JK

,

Griffiths

EA

, et al.

Prolonged survival in bi-allelic TP53-mutated (TP53mut) MDS subjects treated with oral decitabine/ cedazuridine in the Ascertain trial (ASTX727-02)

.

Blood

.

2022

;

140

(

suppl 1

):

2066

-

2069

.

17.

Garcia-Manero

G

,

McCloskey

J

,

Griffiths

EA

, et al.

Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study

.

Lancet Haematol

.

2024

;

11

(

1

):

e15

-

e26

.

18.

DiNardo

CD

,

Jonas

BA

,

Pullarkat

V

, et al.

Azacitidine and venetoclax in previously untreated acute myeloid leukemia

.

N Engl J Med

.

2020

;

383

(

7

):

617

-

629

.

19.

Pratz

KW

,

Jonas

BA

,

Pullarkat

V

, et al.

Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia

.

Am J Hematol

.

2024

;

99

(

4

):

615

-

624

.

20.

Pollyea

DA

,

Pratz

KW

,

Wei

AH

, et al.

Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine

.

Clin Cancer Res

.

2022

;

28

(

24

):

5272

-

5279

.

21.

Kim

K

,

Maiti

A

,

Loghavi

S

, et al.

Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax

.

Cancer

.

2021

;

127

(

20

):

3772

-

3781

.

22.

Schimmer

RR

,

Kovtonyuk

LV

,

Klemm

N

, et al.

TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms

.

Blood Adv

.

2022

;

6

(

11

):

3201

-

3206

.

23.

Badar

T

,

Nanaa

A

,

Atallah

E

, et al.

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

.

Blood Cancer J

.

2024

;

14

(

1

):

32

.

24.

Daver

NG

,

Iqbal

S

,

Renard

C

, et al.

Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis

.

J Hematol Oncol

.

2023

;

16

(

1

):

19

.

25.

Zhang

W

,

Huang

Q

,

Xiao

W

, et al.

Advances in anti-tumor treatments targeting the CD47/SIRPα axis

.

Front Immunol

.

2020

;

11

:

18

.

26.

Feng

D

,

Gip

P

,

McKenna

KM

, et al.

Combination treatment with 5F9 and azacitidine enhances phagocytic elimination of acute myeloid leukemia

.

Blood

.

2018

;

132

(

suppl 1

):

2729

.

27.

Daver

NG

,

Vyas

P

,

Kambhampati

S

, et al.

Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results

.

J Clin Oncol

.

2023

;

41

(

31

):

4893

-

4904

.

28.

Sallman

DA

,

Al Malki

MM

,

Asch

AS

, et al.

Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study

.

J Clin Oncol

.

2023

;

41

(

15

):

2815

-

2826

.

29.

Garcia-Manero

G

,

Daver

NG

,

Xu

J

, et al.

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study

.

J Clin Oncol

.

2021

;

39

(

15 suppl

):

TPS7055

.

. https://www.gilead.com/news-and-press/company-statements/gilead-statement-on-discontinuation-of-phase-3-enhance-3-study-in-aml.

30.

Gilead statement on discontinuation of phase 3 ENHANCE-3 study in AML

. Accessed

20

April

2024

31.

Gilead discontinues phase 3 ENHANCE-2 trial of magrolimab plus azacitidine in TP53-mutant AML

. OncLive.

27

September

2023

. Accessed

20

April

2024

. https://www.onclive.com/view/gilead-discontinues-phase-3-enhance-2-trial-of-magrolimab-plus-azacitidine-in-tp53-mutant-aml.

32.

Deneberg

S

,

Cherif

H

,

Lazarevic

V

, et al.

An open-label phase I dose- finding study of APR-246 in hematological malignancies

.

Blood Cancer J

.

2016

;

6

(

7

):

e447

-

e447

.

33.

Sallman

DA

,

DeZern

AE

,

Garcia-Manero

G

, et al.

Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes

.

J Clin Oncol

.

2021

;

39

(

14

):

1584

-

1594

.

34.

Cluzeau

T

,

Sebert

M

,

Rahmé

R

, et al.

Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des Myélodysplasies (GFM)

.

J Clin Oncol

.

2021

;

39

(

14

):

1575

-

1583

.

35.

Garcia-Manero

G

,

Goldberg

AD

,

Winer

ES

, et al.

Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study

.

Lancet Haematol

.

2023

;

10

(

4

):

e272

-

e283

.

. https://www.targetedonc.com/view/minimal-efficacy-observed-with-eprenetapopt-plus-azacitidine-in-tp53-mutant-mds.

36.

Minimal efficacy observed with eprenetapopt plus azacitidine in TP53- mutant MDS

. Targeted Oncology.

5

January

2021

. Accessed

20

April

2024

37.

Jen

W-Y

,

Konopleva

M

,

Pemmaraju

N.

Tagraxofusp, a first-in-class CD123- targeted agent: five-year postapproval comprehensive review of the literature

.

Cancer

.

2024

;

130

(

13

):

2260

-

2271

.

38.

Lane

AA

,

Garcia

JS

,

Raulston

EG

, et al.

Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia

.

Blood Adv

.

2024

;

8

(

3

):

591

-

602

.

39.

Curigliano

G

,

Gelderblom

H

,

Mach

N

, et al.

Phase I/Ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors

.

Clin Cancer Res

.

2021

;

27

(

13

):

3620

-

3629

.

40.

Schwartz

S

,

Patel

N

,

Longmire

T

, et al.

Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor

.

Immunother Adv

.

2022

;

2

(

1

):

ltac019

.

41.

Brunner

AM

,

Esteve

J

,

Porkka

K

, et al.

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes

.

Am J Hematol

.

2024

;

99

(

2

):

E32

-

E36

.

42.

Zeidan

AM

,

Ando

K

,

Rauzy

O

, et al.

Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo- controlled, phase 2 trial

.

Lancet Haematol

.

2024

;

11

(

1

):

e38

-

e50

.

43.

de Silva

S

,

Fromm

G

,

Shuptrine

CW

, et al.

CD40 enhances type I interferon responses downstream of CD47 blockade, bridging innate and adaptive immunity

.

Cancer Immunol Res

.

2020

;

8

(

2

):

230

-

245

.

44.

Daver

N

,

Selwyn Stein

A

,

Bixby

D

, et al.

Safety, pharmacodynamic, and anti-tumor activity of SL-172154 as monotherapy and in combination with azacitidine (AZA) in relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) patients (pts)

.

Blood

.

2023

;

142

(

suppl 1

):

4278

.

45.

Zhang

X

,

Lv

H

,

Xiao

X

, et al.

A phase I clinical trial of CLL-1 CAR-T cells for the treatment of relapsed/refractory acute myeloid leukemia in adults

.

Blood

.

2023

;

142

(

suppl 1

):

2106

.

46.

Mueller

J

,

Schimmer

RR

,

Koch

C

, et al.

Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells

.

EMBO Mol Med

.

2024

;

16

(

3

):

445

-

474

.

47.

Uy

GL

,

Aldoss

I

,

Foster

MC

, et al.

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

.

Blood

.

2021

;

137

(

6

):

751

-

762

.

48.

Vadakekolathu

J

,

Lai

C

,

Reeder

S

, et al.

TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML

.

Blood Adv

.

2020

;

4

(

20

):

5011

-

5024

.

49.

Dumbrava

EE

,

Johnson

ML

,

Tolcher

AW

, et al.

First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation

.

J Clin Oncol

.

2022

;

40

(

16 suppl

):

3003

.

50.

Carter

BZ

,

Mak

PY

,

Ke

B

, et al.

Selective targeting of TP53-Y220C mutant AML by PC14586 results in TP53 wild-type conformation and synergistical apoptosis induction by concomitant inhibition of Xpo-1, MDM2, or Bcl-2

.

Blood

.

2023

;

142

(

suppl 1

):

2261

.

51.

Parrales

A

,

Ranjan

A

,

Iyer

SV

, et al.

DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway

.

Nat Cell Biol

.

2016

;

18

(

11

):

1233

-

1243

.

52.

Hsiue

EH

,

Wright

KM

,

Douglass

J

, et al.

Targeting a neoantigen derived from a common TP53 mutation

.

Science

.

2021

;

371

(

6533

):

eabc8697

.

53.

Lancet

JE

,

Uy

GL

,

Cortes

JE

, et al.

CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia

.

J Clin Oncol

.

2018

;

36

(

26

):

2684

-

2692

.